Warner Chilcott, Watson Settle Birth Control Dispute

Law360, New York (January 12, 2009, 12:00 AM EST) -- Warner Chilcott Ltd. and Watson Pharmaceuticals Inc. have reached a settlement in their patent dispute that will allow Watson to produce generic versions of the birth control pills Loestrin 24 and Femcon Fe.

Under a nonexclusive patent license, Watson will begin marketing generic Loestrin either Jan. 22, 2014, or the date that another generic version of the product enters the U.S. market, whichever is earlier, the drugmakers said in a joint statement Monday.

The agreement covering Femcon, Warner Chilcott's chewable contraceptive, will allow Watson to start...
To view the full article, register now.